[go: up one dir, main page]

WO2016040373A1 - Mimetiques de mir-29 et leurs utilisations - Google Patents

Mimetiques de mir-29 et leurs utilisations Download PDF

Info

Publication number
WO2016040373A1
WO2016040373A1 PCT/US2015/049018 US2015049018W WO2016040373A1 WO 2016040373 A1 WO2016040373 A1 WO 2016040373A1 US 2015049018 W US2015049018 W US 2015049018W WO 2016040373 A1 WO2016040373 A1 WO 2016040373A1
Authority
WO
WIPO (PCT)
Prior art keywords
mir
strand
seq
sequence
mimetic compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/049018
Other languages
English (en)
Inventor
Rusty L. Montgomery
Christina Dalby
Eva Van Rooij
Corrie Gallant-Behm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viridian Therapeutics Inc
Original Assignee
Miragen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2015315298A priority Critical patent/AU2015315298B2/en
Priority to JP2017513109A priority patent/JP6837963B2/ja
Priority to KR1020177008019A priority patent/KR20170068452A/ko
Priority to BR112017004648A priority patent/BR112017004648A2/pt
Priority to RU2017111775A priority patent/RU2712511C2/ru
Priority to EP15840320.4A priority patent/EP3201213B1/fr
Priority to CA2960387A priority patent/CA2960387A1/fr
Priority to MX2017003018A priority patent/MX382425B/es
Application filed by Miragen Therapeutics Inc filed Critical Miragen Therapeutics Inc
Priority to CN201580057333.0A priority patent/CN107108685B/zh
Publication of WO2016040373A1 publication Critical patent/WO2016040373A1/fr
Priority to IL250952A priority patent/IL250952A0/en
Priority to PH12017500424A priority patent/PH12017500424A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance

Definitions

  • the present invention relates to synthetic miRNA mimics or promiRs that increase miRNA activity in vivo.
  • the present invention relates to mimics of miR-29 and their use in reducing collagen deposition and associated conditions, such as fibrosis.
  • miRNAs are important players during disease.
  • These studies combined with recent positive clinical efficacy data (Janssen et al, 2013), underscore the relevance of miRNAs and the viability for miRNAs to become the next class of therapeutics.
  • miRNAs have several advantages as therapeutic intervention points in that they are small and comprise a known sequence. Additionally, since a single miRNA can regulate numerous target mRNAs within biological pathways, modulation of a miRNA in principle allows for influencing an entire gene network and modifying complex disease phenotypes (van Rooij & Olson, 2012).
  • miRNA function can be increased either by viral overexpression or by using synthetic double-stranded miRNAs.
  • AAV adeno-associated viruses
  • the microRNA-29 (miR-29) family is well characterized for their ability to regulate extracellular matrix proteins (He et al, 2013).
  • the family consists of miR-29a, -29b and -29c, which are expressed as two bicistronic clusters (miR-29a/-29b-l and miR-29b-2/-29c), and are largely homologous in sequence with only a few mismatches between the different members in the 3' regions of the mature miRNA (van Rooij et al, 2008).
  • the present invention is based, in part, on the discovery that miRNA mimics with modifications for stability and cellular uptake can be used to replicate endogenous functions of miR-29.
  • miRNA mimics with modifications for stability and cellular uptake can be used to replicate endogenous functions of miR-29.
  • therapeutic treatment with a miR-29b mimic in the setting of pulmonary fibrosis restores the bleomycin-induced reduction of miR-29 and blocks and reverses pulmonary fibrosis, which coincides with a repression of miR-29 target genes that are induced during the disease process.
  • treatment of skin incisions with a miR-29b mimic down-regulates the expression of extra-cellular matrix genes and other genes involved in the fibrotic process.
  • the present invention provides double-stranded RNA miR-29 mimetic compounds.
  • the miR-29 mimetic compound comprises (a) a first strand of about 23 to about 26 ribonucleotides comprising a mature miR-29a, miR-29b, or miR-29c sequence; and (b) a second strand of about 22 to about 23 ribonucleotides comprising a sequence that is substantially complementary to the first strand, wherein the first strand has a 3' nucleotide overhang relative to the second strand.
  • the first strand and second strand contain one or more modified nucleotides.
  • the modified nucleotides may be 2' sugar modifications, such as 2'-alkyl (2'-0-methyl) or 2'-fluoro modifications.
  • the first strand has one or more 2'-fluoro modifications.
  • the second strand has one or more 2'-0-methyl modifications.
  • the second strand has one, two, three, or more mismatches relative to the first strand.
  • the second strand of a miR-29 mimetic compound contains mismatches at positions 4, 13, and/or 16 from the 3' end (of the second strand) relative to the first strand.
  • the second strand of the miR-29 mimetic compound is linked to a cholesterol molecule at its 3' terminus.
  • the cholesterol molecule is linked to the second strand through at least a six carbon linker.
  • the linker may be a cleavable linker.
  • the nucleotides comprising the 3' overhang in the first strand are linked by phosphorothioate linkages.
  • the miR-29 mimetic compound comprises a first strand comprising the sequence of SEQ ID NO: 27 and a second strand comprising the sequence of SEQ ID NO: 5.
  • the miR-29 mimetic compound comprises a first strand comprising the sequence of SEQ ID NO: 19 and a second strand comprising the sequence of SEQ ID NO: 1.
  • the miR-29 mimetic compound comprises a first strand comprising the sequence of SEQ ID NO: 19 and a second strand comprising the sequence of SEQ ID NO: 15.
  • the miR-29 mimetic compound comprises a first strand comprising the sequence of SEQ ID NO: 33 and a second strand comprising the sequence of SEQ ID NO: 1.
  • the miR-29 mimetic compound comprises a first strand comprising the sequence of SEQ ID NO: 34 and a second strand comprising the sequence of SEQ ID NO: 1.
  • the miR-29 mimetic compound comprises a first strand comprising the sequence of SEQ ID NO: 35 and a second strand comprising the sequence of SEQ ID NO: 24.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising an effective amount of the miR-29 mimetic compounds described herein or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier or diluent.
  • the pharmaceutical composition is formulated for pulmonary, nasal, intranasal or ocular delivery and can be in the form of powders, aqueous solutions, aqueous aerosols, nasal drops, aerosols, and/or ocular drops.
  • the pharmaceutical composition is administered with an inhalation system such as a nebulizer, a metered dose inhaler, a dry powder inhaler, or a soft mist inhaler.
  • the present invention also includes a method of regulating an extracellular matrix gene in a cell comprising contacting the cell with the miR-29 mimetic compounds described herein.
  • the expression or activity of the extracellular matrix gene is reduced following contact with the miR-29 mimetic compound or composition.
  • the extracellular matrix gene is a collagen gene, such as Collal and Co al .
  • the cell may be in vitro, in vivo, or ex vivo.
  • the present invention provides a method of treating or preventing tissue fibrosis in a subject in need thereof.
  • the method comprises administering to the subject a miR-29 mimetic compound described herein.
  • the tissue fibrosis is cardiac fibrosis, pulmonary fibrosis, renal fibrosis, hepatic fibrosis, ocular fibrosis, cutaneous fibrosis including hypertrophic scarring and keloids, hand, joint or tendon fibrosis, Peyronie's disease or scleroderma.
  • the tissue fibrosis is idiopathic pulmonary fibrosis (IPF).
  • the method for treating or preventing tissue fibrosis comprises administering a miR-29 mimetic compound or a composition described herein via the pulmonary, nasal, or intranasal route.
  • the miR-29 mimetic compound or the composition is delivered via inhalation.
  • the present invention also includes a method of regulating non-extracellular matrix genes in a cell comprising contacting the cell with the miR-29 mimetic compounds described herein.
  • the expression or activity of the non-extracellular matrix gene is increased following contact with the miR-29 mimetic compound or composition.
  • the non-extracellular matrix gene is a gene such as Itga3 or Numb.
  • the cell may be in vitro, in vivo, or ex vivo.
  • the present invention also provides a method for assessing the efficacy of a treatment with a miR-29 agonist or miR-29 antagonist, the method comprising determining a level of expression of one or more genes in cells or a fibrotic tissue of a subject prior to the treatment with the miR-29 agonist or miR-29 antagonist, wherein the one or more genes are selected from a set of genes modulated by miR-29; determining the level of expression of the same one or more genes in cells/fibrotic tissue of the subject after treatment with the miR-29 agonist or miR-29 antagonist; and determining the treatment to be effective, less effective, or not effective based on the expression levels prior to and after the treatment.
  • the one or more genes modulated by miR-29 are selected from Table 5.
  • FIG. 1A The double-stranded miR-29 mimics design contains a 'guide strand' or 'antisense strand' that is identical to the miR-29b, with a UU overhang on the 3' end, modified to increase stability, and chemically phosphorylated on the 5 ' end and a 'passenger strand' or 'sense strand' that contains 2'-0-Me modifications to prevent loading into RNA- induced silencing complex (RISC) as well as increase stability and is linked to cholesterol for enhanced cellular uptake.
  • RISC RNA- induced silencing complex
  • FIG. IB Transfection experiments in NIH 3T3 show a dose-dependent decrease in Collal with increasing amount of miR-29b mimic compared to either untreated or mock treated cells. An siRNA directly targeting Collal was taken along as a positive control. * p ⁇ 0.05 versus mock, # p ⁇ 0.05 versus untreated.
  • FIG. 1C Northern blot analysis for miR-29b in different tissues 4 days after intravenous injection with 10, 50, 100, or 125 mpk miR-29b mimic indicates delivery to all tissues at the highest dose, with the most effective delivery taking place to the lungs and spleen compared to saline injected mice.
  • U6 is used as a loading control.
  • FIG. IE Northern blot analysis for miR-29b in different tissues 1, 2, 4 and 7 days after intravenous injection with 125 mpk of mimic indicates the presence of miR-29b mimic in all tissues examined, with a longer detection in lung and spleen.
  • U6 is used as a loading control.
  • FIG. 2A Real-time PCR analysis indicates a reduction in all miR-29 family members in response to bleomycin, while miR-29 mimic treatment resulted in the increased detection of miR-29b levels compared to either control or saline injected animals. *p ⁇ 0.05 vs Saline/Saline
  • FIG. 2B Real-time PCR analysis indicated a comparable decline in miR-29 levels in pulmonary biopsies of patients with idiopathic pulmonary fibrosis (IPF) compared to normal controls. *p ⁇ 0.05 vs Normal
  • FIG. 2C Histological examination by trichrome staining showing pronounced fibrotic and inflammatory response in response to bleomycin, which was blunted by miR-29b mimic treatment. Scale bar indicates 100 ⁇ .
  • FIG. 2D Hydroxyproline measurements to assay for total collagen content showed a significant increase following bleomycin treatment in both saline and control treated groups, while there was no statistical difference in the miR-29 mimic treated group between Saline and bleomycin treated mice.
  • FIG. 3A-B Bleomycin treatment increases the expression of Collal and Co al and the presence of miR-29b mimic inhibits Collal and CoBal as measured by real-time PCR.
  • FIG. 3D Immunohistochemistry demonstrated robust detection of IGF1 after bleomycin treatment, which was reduced in the miR-29b mimic treated group compared to Saline or Control mimic treated mice. Scale bar indicates 50um.
  • FIG. 4D Histological examination by trichrome staining showing robust fibrosis in response to bleomycin, which was blunted by miR-29b mimic treatment.
  • FIG. 4E-F Primary pulmonary fibroblasts from patients with IPF were treated with vehicle or TGF- ⁇ and transfected with control mimic or miR-29b mimic. Real-time PCR was performed for Collal (E) and CoBal (F). miR-29b mimic treatment showed a dose- dependent reduction in both collagens.
  • FIG. 4G-H A549 cells were treated with vehicle or TGF- ⁇ and transfected with control mimic or miR-29b mimic. Real-time PCR was performed for Collal (G) and CoBal (H). miR-29b mimic treatment showed a dose-dependent reduction in expression of both Collal and CoBal .
  • miR-29b mimic does not induce general signs of toxicity.
  • miR-29b mimic specifically increases miR-29b.
  • MiR-29b mimicry specifically increases the level of miR-29b without affecting the level of miR-29a or miR-29c compared to Saline injected mice.
  • the increase in miR-29c at day 1 might be due to some cross-reactivity of the real-time probe.
  • n 4 per group.
  • Real-time PCR analysis showed significant increases in Csf3, Igfl, and Kc expression after miR-29b mimic treatment compared to vehicle or control mimic. * p ⁇ 0.05 compared to Vehicle injected.
  • FIG. 10A miR29b mimic and antimiR effects on gene expression in mouse skin.
  • a heatmap of the microarray data is presented, where upregulated genes are represented in red and downregulated genes are represented in blue, and the intensity of the color is representative of the fold change relative to PBS control.
  • the top portion of the heatmap (finely dashed box) contains genes which are repressed by miR-29b mimic treatment and upregulated by antimiR-29 treatment
  • the bottom portion of the heatmap (wide dashed box) contains genes which are upregulated by miR-29b mimic treatment and repressed by antimiR-29 treatment. All fold change and significance values are presented in Table 5.
  • FIG. 10B miR29b mimic and antimiR effects on gene expression in mouse skin.
  • DAVID analysis NCBI
  • Gene Ontology GO
  • terms of Extracellular Matrix, (Skin) Function, Adhesion/Cell Signaling and Cell Differentiation/ Apoptosis are the top negatively regulated pathways following miR-29b mimic treatment
  • Cellular (Nuclear) Structure and RNA Processing are the top positively regulated pathways following miR-29b mimic treatment.
  • microarray analysis of skin and acute skin wounds in C57BL/6 mice shows reciprocal regulation of 228 genes by intradermal treatment with a miR-29b mimic comprising SEQ ID NO: 2 and SEQ ID NO: 1, and antimiR-29 (SEQ ID NO: 36).
  • FIG. 11 A Quantitative real-time (RT)-PCR analysis of mouse incisional wounds treated with intradermal miR-29b mimic (SEQ ID NO: 2/SEQ ID NO: 1) or PBS control. Data are presented as a grouped bar graph where the first bar in each treatment group represents the expression level of the first gene in the list on the right, and so on.
  • RT-PCR confirmed that collagens, other extracellular matrix genes and other direct and indirect target genes previously shown to be repressed by miR-29b mimic treatment (Figure 10a, upper half of the heatmap) show a dose-dependent reduction in expression with miR-29b mimic treatment in acute skin wounds.
  • FIG. 11B Genes previously identified as being de-repressed with miR-29b mimic treatment ( Figure 10A, lower half of the heatmap) show a dose-dependent increase in expression with miR-29b mimic treatment by quantitative RT-PCR. *** p ⁇ 0.001 and **** p ⁇ 0.0001 versus PBS treated incisions, using a 2-way ANOVA with treatment and gene as the two factors assessed.
  • the miR-29b mimic significantly affects the expression of miR-29 target genes in acute skin wounds.
  • FIG. 12 Activity of miR-29 mimics and effects of nucleotide modifications. Transfection experiments in IMR-90 human lung fibroblasts show that different miR-29 mimics have different levels of activity as measured by repression of collagen gene expression. * p ⁇ 0.05, *** p ⁇ 0.001 and **** p ⁇ 0.0001 versus mock transfection, using a 2- way ANOVA with treatment and gene as the two factors assessed.
  • FIG. 13 In vivo activity of miR-29b mimics with linker modifications. Mice with incisional wounds were treated with 20 nmol of various miR-29b mimics that differ only in the linkage between the cholesterol moiety and the second/sense strand. Activity of the miR- 29b mimics was determined by measuring the expression of five collagen synthesis genes.
  • FIG. 14 Effect of 5' phosphorylation on the activity of miR-29b mimics.
  • RAB-9 skin fibroblasts were transfected with varying concentrations of miR-29b mimics with (SEQ ID NO: 2/SEQ ID NO: 1) and without (SEQ ID NO: 19/SEQ ID NO: 1) 5' phosphorylation on the antisense strand.
  • Activity of the miR-29b mimics was determined by measuring the expression of three collagen synthesis genes.
  • miRNA microRNA
  • the miR-29 family has gained a lot of attention for its clear function in tissue fibrosis.
  • This fibroblast-enriched miRNA family is downregulated in fibrotic diseases which induces a coordinate increase of many extracellular matrix genes.
  • the present inventors have found that administration of synthetic RNA duplexes can increase miR-29 levels in vivo for several days.
  • therapeutic delivery of these miR-29 mimics during bleomycin-induced pulmonary fibrosis restores endogenous miR-29 function thereby decreasing collagen expression and blocking and reversing pulmonary fibrosis.
  • administration of miR-29 mimics of the present invention to skin incisions downregulates extracellular matrix genes and other genes involved in the fibrotic process.
  • the present invention provides miR- 29 mimics, compositions and uses thereof.
  • a microRNA mimetic compound according to the invention comprises a first strand and a second strand, wherein the first strand comprises a mature miR-29a, miR-29b, or miR- 29c sequence and the second strand comprises a sequence that is substantially complementary to the first strand and has at least one modified nucleotide.
  • microRNA mimetic compound may be used interchangeably with the terms “promiR- 29,” “miR-29 agonist,” “microRNA agonist,” “microRNA mimic,” “miRNA mimic,” or “miR-29 mimic;” the term “first strand” may be used interchangeably with the terms “antisense strand” or “guide strand”; the term “second strand” may be used interchangeably with the term “sense strand” or “passenger strand;” and the term “miR-29 antagonist” may be used interchangeably with the terms “oligonucleotide inhibitor,” “antimiR-29,” “antisense oligonucleotide,” “miR-29 antagomir” or “anti-microRNA oligonucleotide.”
  • the first strand of the microRNA mimetic compound comprises from about 23 to about 26 nucleotides comprising a sequence of mature miR-29a, miR-29b, or miR-29c and the second strand comprises from about 22 to about 23 nucleotides comprising a sequence that is partially, substantially, or fully complementary to the first strand.
  • the first strand may comprise about 23, 24, 25, or 26 nucleotides and the second strand may comprise about 22 or 23 nucleotides.
  • the nucleotides that form the first and the second strand of the microRNA mimetic compounds may comprise ribonucleotides, deoxyribonucleotides, modified nucleotides, and combinations thereof.
  • the first strand and the second strand of the microRNA mimetic compound comprise ribonucleotides and/or modified ribonucleotides.
  • modified nucleotide means a nucleotide where the nucleobase and/or the sugar moiety is modified relative to unmodified nucleotides.
  • the microRNA mimetic compounds have a first strand or an antisense strand, whose sequence is identical to all or part of a mature miR-29a, miR-29b, or miR-29c sequence, and a second strand or a sense strand whose sequence is about 70% to about 100% complementary to the sequence of the first strand.
  • the first strand of the miRNA mimetic compound is at least about 75, 80, 85, 90, 95, or 100% identical, including all integers there between, to the entire sequence of a mature, naturally occurring miR-29a, miR-29b, or miR-29c sequence.
  • the first strand is about or is at least about 90, 91 , 92, 93, 94, 95, 96, 97, 98, 99, or 100% identical to the sequence of a mature, naturally-occurring miRNA, such as the mouse, human, or rat miR- 29a, miR-29b, or miR-29c sequence.
  • the first strand may comprise 20, 21 , 22, or 23 nucleotide positions in common with a mature, naturally-occurring miRNA as compared by sequence alignment algorithms and methods well known in the art.
  • sequence of the first strand is considered to be identical to the sequence of a mature miR-29a, miR-29b, or miR-29c even if the first strand includes a modified nucleotide instead of a naturally-occurring nucleotide.
  • the first strand of the mimetic compound may comprise a modified cytidine nucleotide, such as 2'-fluoro-cytidine, at the corresponding position or if a mature, naturally-occurring miRNA sequence comprises a uridine nucleotide at a specific position, the miRNA region of the first strand of the mimetic compound may comprise a modified uridine nucleotide, such as 2'-fluoro-uridine, 2'-0-methyl-uridine, 5-fluorouracil, or 4-thiouracil at the corresponding position.
  • a modified cytidine nucleotide such as 2'-fluoro-cytidine
  • the sequence of the first strand is considered to be identical to the mature, naturally-occurring miRNA sequence.
  • the first strand may include a modification of the 5 '-terminal residue.
  • the first strand may have a 5 '-terminal monophosphate.
  • the first strand does not contain a 5 '-terminal monophosphate.
  • the second strand of the microRNA mimic is partially complementary to the sequence of the first strand.
  • the sequence of the second strand is at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%, inclusive of all values therebetween, complementary to the sequence of the first strand.
  • the second strand is substantially complementary to the sequence of the first strand.
  • the second strand is at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, inclusive of all values therebetween, complementary to the sequence of the first strand.
  • the sequence of the second strand may be fully complementary to the first strand. In certain embodiments, about 19, 20, 21, 22, or 23 nucleotides of the complementary region of the second strand may be complementary to the first strand.
  • the sequence of the second strand is considered to be complementary to the first strand even if the second strand includes a modified nucleotide instead of a naturally-occurring nucleotide.
  • the first strand sequence comprises a guanosine nucleotide at a specific position
  • the second strand may comprise a modified cytidine nucleotide, such as 2'-0-methyl-cytidine, at the corresponding position.
  • the second strand comprises about 1, 2, 3, 4, 5, or 6 mismatches relative to the first strand. That is, up to 1, 2, 3, 4, 5, or 6 nucleotides between the first strand and the second strand may not be complementary.
  • the mismatches are not consecutive and are distributed throughout the second strand. In another embodiment, the mismatches are consecutive and may create a bulge.
  • the second strand contains 3 mismatches relative to the first strand.
  • the second strand of a miR-29a mimic or a miR-29c mimic contains mismatches at positions 4, 13, and/or 16 from the 3' end (of the second strand) relative to the first strand.
  • the second strand of a miR-29b mimic contains mismatches at positions 4, 13, and/or 16 from the 3' end (of the second strand) relative to the first strand. In another embodiment, the second strand of a miR-29b mimic contains mismatches at positions 4, 9, 10, 11, 13 and/or 16 from the 3' end (of the second strand) relative to the first strand.
  • the first and/or the second strand of the mimetic compound may comprise an overhang on the 5' or 3' end of the strands.
  • the first strand comprises a 3' overhang, i.e., a single-stranded region that extends beyond the duplex region, relative to the second strand.
  • the 3' overhang of the first strand may range from about one nucleotide to about four nucleotides.
  • the 3' overhang of the first strand may comprise 1 or 2 nucleotides.
  • the nucleotides comprising the 3' overhang in the first strand are linked by phosphorothioate linkages.
  • the nucleotides comprising the 3' overhang in the first strand may include ribonucleotides, deoxyribonucleotides, modified nucleotides, or combinations thereof.
  • the 3' overhang in the first strand comprises two ribonucleotides.
  • the 3' overhang of the first strand comprises two uridine nucleotides linked through a phosphorothioate linkage.
  • the first strand may not contain an overhang.
  • nucleotides in the second/sense strand of miR-29 mimics of the invention are linked by phosphodiester linkages and the nucleotides in the first/antisense strand are linked by phosphodiester linkages except for the last three nucleotides at the 3 ' end which are linked to each other via phosphorothioate linkages.
  • miR-29 mimics of the present invention comprise modified nucleotides.
  • the first strand of the mimic comprises one or more 2'-fluoro nucleotides.
  • the first strand may not include any modified nucleotide.
  • the second strand comprises one or more 2'-0- methyl modified nucleotides.
  • miR-29 mimics according to the present invention comprise first and second strands listed in the Tables below. Definitions of the modifications are presented in Table 4. These miR-29 mimetic compounds are useful for regulating the expression of extracellular matrix genes in a cell and treating associated conditions, such as tissue fibrosis, dermal fibrosis, including the uses and conditions described in WO 2009/018493, which is hereby incorporated by reference in its entirety.
  • a miR-29a mimic comprises a first strand comprising SEQ ID NO: 27 and a second strand comprising SEQ ID NO: 5. In other embodiments, a miR-29a mimic comprises a first strand comprising SEQ ID NO: 7 and a second strand comprising SEQ ID NO: 5.
  • a miR-29b mimic comprises a first strand comprising SEQ ID NO: 19 and a second strand comprising SEQ ID NO: 1.
  • a miR- 29b mimic comprises a first strand comprising SEQ ID NO: 2 and a second strand comprising SEQ ID NO: 1.
  • a miR-29b mimic comprises a first strand comprising SEQ ID NO: 19 and a second strand comprising SEQ ID NO: 15.
  • a miR-29b mimic comprises a first strand comprising SEQ ID NO: 33 and a second strand comprising SEQ ID NO: 1.
  • a miR-29b mimic comprises a first strand comprising SEQ ID NO: 34 and a second strand comprising SEQ ID NO: 1. In yet some other embodiments, a miR-29b mimic comprises a first strand comprising SEQ ID NO: 19 and a second strand comprising SEQ ID NO: 30.
  • a miR-29c mimic comprises a first strand comprising SEQ ID NO: 35 and a second strand comprising SEQ ID NO: 24. In other embodiments, a miR- 29c mimic comprises a first strand comprising SEQ ID NO: 26 and a second strand comprising SEQ ID NO: 24.
  • the modified nucleotides that may be used in the microRNA mimetic compounds of the invention can include nucleotides with a base modification or substitution.
  • the natural or unmodified bases in RNA are the purine bases adenine (A) and guanine (G), and the pyrimidine bases cytosine (C) and uracil (U) (DNA has thymine (T)).
  • modified bases also referred to as heterocyclic base moieties
  • modified bases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and
  • the microRNA mimetic compounds can have nucleotides with modified sugar moieties.
  • modified sugars include carbocyclic or acyclic sugars, sugars having substituent groups at one or more of their 2', 3' or 4' positions and sugars having substituents in place of one or more hydrogen atoms of the sugar.
  • the sugar is modified by having a substituent group at the 2' position.
  • the sugar is modified by having a substituent group at the 3' position.
  • the sugar is modified by having a substituent group at the 4' position.
  • a sugar may have a modification at more than one of those positions, or that an RNA molecule may have one or more nucleotides with a sugar modification at one position and also one or more nucleotides with a sugar modification at a different position.
  • Sugar modifications contemplated in the miRNA mimetic compounds include, but are not limited to, a substituent group selected from: OH; F; 0-, S-, or N-alkyl; 0-, S-, or N- alkenyl; 0-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted Ci to Cio alkyl or C 2 to Cio alkenyl and alkynyl.
  • miRNA mimetic compounds have a sugar substituent group selected from the following: Ci to C 10 lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH 3 , CI, Br, CN, OCN, CF 3 , OCF 3 , SOCH 3 , S0 2 CH 3 , ON0 2 , N0 2 , N 3 , NH 2 , heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, or similar substituents.
  • a sugar substituent group selected from the following: Ci to C 10 lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH 3 , CI, Br, CN, OCN, CF 3 , OCF 3 , SOCH 3 , S0 2 CH
  • the modification includes 2'-methoxyethoxy (2'-0- CH 2 CH 2 OCH 3 , which is also known as 2'-0-(2-methoxyethyl) or 2'-MOE), that is, an alkoxyalkoxy group.
  • Another modification includes 2'-dimethylaminooxyethoxy, that is, a 0(CH 2 ) 2 ON(CH 3 ) 2 group, also known as 2'-DMAOE and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-0-dimethyl-amino-ethoxy-ethyl or 2'-DMAEOE), that is, 2'-0- CH 2 -0-CH 2 -N(CH 3 ) 2 .
  • Sugar substituent groups on the 2' position (2'-) may be in the arabino (up) position or ribo (down) position.
  • One 2 '-arabino modification is 2'-F.
  • Other similar modifications may also be made at other positions on the sugar moiety, particularly the 3 ' position of the sugar on the 3' terminal nucleoside or in 2 '-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide.
  • the sugar modification is a 2'-0-alkyl (e.g. 2'-0-methyl, 2'- O-methoxyethyl), 2'-halo (e.g., 2'-fluoro, 2'-chloro, 2'-bromo), and 4' thio modifications.
  • the first strand of the miR-29a, miR-29b, or miR-29c mimetic compound comprises one or more 2' fluoro nucleotides.
  • the first strand of the mimetic compounds has no modified nucleotides.
  • the second strand of miR-29a, miR-29b, or miR-29c mimetic compound comprises one or more 2'-0-methyl modified nucleotides.
  • the first and the second strand of microRNA mimetic compounds of the invention can also include backbone modifications, such as one or more phosphorothioate, morpholino, or phosphonocarboxylate linkages (see, for example, U.S. Patent Nos. 6,693,187 and 7,067,641, which are herein incorporated by reference in their entireties).
  • backbone modifications such as one or more phosphorothioate, morpholino, or phosphonocarboxylate linkages (see, for example, U.S. Patent Nos. 6,693,187 and 7,067,641, which are herein incorporated by reference in their entireties).
  • the nucleotides comprising the 3 ' overhang in the first strand are linked by phosphorothioate linkages.
  • the microRNA mimetic compounds are conjugated to a carrier molecule such as a steroid (cholesterol), a vitamin, a fatty acid, a carbohydrate or glycoside, a peptide, or other small molecule ligand to facilitate in vivo delivery and stability.
  • a carrier molecule such as a steroid (cholesterol), a vitamin, a fatty acid, a carbohydrate or glycoside, a peptide, or other small molecule ligand to facilitate in vivo delivery and stability.
  • the carrier molecule is attached to the second strand of the microRNA mimetic compound at its 3' or 5' end through a linker or a spacer group.
  • the carrier molecule is cholesterol, a cholesterol derivative, cholic acid or a cholic acid derivative.
  • the carrier molecule is cholesterol and it is attached to the 3 ' or 5 ' end of the second strand through at least a six carbon linker. In one embodiment, the carrier molecule is attached to the 3 ' end of the second strand through a six or nine carbon linker.
  • the linker is a cleavable linker. In various embodiments, the linker comprises a substantially linear hydrocarbon moiety. The hydrocarbon moiety may comprise from about 3 to about 15 carbon atoms and may be conjugated to cholesterol through a relatively non-polar group such as an ether or a thioether linkage.
  • the hydrocarbon linker/spacer comprises an optionally substituted C2 to C15 saturated or unsaturated hydrocarbon chain (e.g. alkylene or alkenylene).
  • a variety of linker/spacer groups described in U.S. Pre-grant Publication No. 2012/0128761, which is incorporated by reference herein in its entirety, can be used in the present invention.
  • the present invention provides methods of treating, ameliorating, or preventing fibrotic conditions in a subject in need thereof comprising administering to the subject a therapeutically effective amount of at least one of a miR-29a, miPv-29b, and/or miR-29c mimic described herein.
  • Fibrotic conditions that may be treated using miPv-29 mimics of the invention include, but are not limited to, tissue fibrosis such as pulmonary fibrosis, cardiac fibrosis, hepatic fibrosis, kidney fibrosis, diabetic fibrosis, skeletal muscle fibrosis, and ocular fibrosis; and dermal/cutaneous fibrosis such as keloids, cutaneous sclerosis, systemic sclerosis (scleroderma), hypertrophic scars, hand/joint/tendon fibrosis, and Peyronie's disease.
  • the fibrotic condition treated using the miPv-29 mimics of the invention is idiopathic pulmonary fibrosis.
  • miR-29 agonists in treating certain fibrotic conditions is described in U.S. Patent No. 8,440,636, which is hereby incorporated by reference herein.
  • administration of miR-29 mimics of the present invention reduces the expression or activity one or more extracellular matrix genes in cells of the subject.
  • administration of miR-29 mimics of the present invention reduces the expression or activity one or more collagen synthesis genes in cells of the subject.
  • administration of miR-29 mimics up-regulates the expression or activity one or more genes involved in the skin development, epidermis development, ectoderm development and cellular homeostasis.
  • Cells of the subject where the expression or activity of various genes is regulated by miR-29 mimics of the invention include fibroblasts and epidermal cells.
  • administration of miR-29 mimics down- regulates inflammatory responses associated with fibrosis.
  • miR-29 mimics reduces the levels of pro-inflammatory cytokines such as IL-12, IL-4, GCSF, and TNF-a in fibrosis patients.
  • Administration of miR-29 mimics may also reduce infiltration of immune effector cells such as neutrophils, lymphocytes, monocytes, and macrophages in fibrotic tissues or organs.
  • the present invention provides methods of regulating an extracellular matrix gene in a cell comprising contacting the cell with a miR-29 mimic of the present invention.
  • the invention provides methods of regulating a collagen synthesis gene in a cell comprising contacting the cell with a miR-29 mimic of the present invention.
  • the miR-29 mimic reduces the expression or activity of the extracellular matrix gene or the collagen synthesis gene.
  • the term "subject" or “patient” refers to any vertebrate including, without limitation, humans and other primates (e.g., chimpanzees and other apes and monkey species), farm animals (e.g., cattle, sheep, pigs, goats and horses), domestic mammals (e.g., dogs and cats), laboratory animals (e.g., rabbits, rodents such as mice, rats, and guinea pigs), and birds (e.g., domestic, wild and game birds such as chickens, turkeys and other gallinaceous birds, ducks, geese, and the like).
  • the subject is a mammal. In other embodiments, the subject is a human.
  • the invention also provides methods for assessing the efficacy of a treatment with miR-29 agonists (e.g. drugs or miR-29 mimics) or miR-29 antagonists (e.g. drugs or antimiR- 29).
  • the method for assessing the treatment efficacy comprises determining a level of expression of one or more genes in cells or a fibrotic tissue of a subject prior to the treatment with miR-29 mimics or miR-29 antagonists, wherein the one or more genes are selected from a set of genes modulated by miR-29, e.g.
  • genes listed in Table 5 determining the level of expression of the same one or more genes in cells/fibrotic tissue of the subject after treatment with miR-29 mimics or miR-29 antagonist; and determining the treatment to be effective, less effective, or not effective based on the expression levels prior to and after the treatment. That is, in one embodiment, the genes listed in Table 5 serve as a biomarker for clinical efficacy of the miR-29 mimic or miR-29 antagonist treatment. In one embodiment, a statistically significant difference in the expression of the genes prior to and after treatment indicates the treatment to be effective. In another embodiment, at least 1-fold, 1.5-fold, 2-fold, 2.5-fold, 3-fold, 3.5-fold, or 4-fold difference in the expression of the genes prior to and after treatment indicates the treatment to be effective.
  • the present invention also provides pharmaceutical compositions comprising a therapeutically effective amount of one or more microRNA mimetic compounds of miR-29a, miR-29b, and/or miR-29c according to the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
  • the pharmaceutical composition comprises a therapeutically effective amount of a miR-29a mimetic compound and a pharmaceutically acceptable carrier or excipient, wherein the first strand of the mimetic compound comprises a mature miR-29a sequence and the second strand is substantially complementary to the first strand.
  • the pharmaceutical composition comprises a therapeutically effective amount of a miR-29b mimetic compound and a pharmaceutically acceptable carrier or excipient, wherein the first strand of the mimetic compound comprises a mature miR-29b sequence and the second strand is substantially complementary to the first strand.
  • the pharmaceutical composition comprises a therapeutically effective amount of a miR-29c mimetic compound and a pharmaceutically acceptable carrier or excipient, wherein the first strand of the mimetic compound comprises a mature miR-29c sequence and the second strand is substantially complementary to the first strand.
  • the pharmaceutical composition comprises a therapeutically effective amount of at least two microRNA mimetic compounds of the invention and a pharmaceutically acceptable carrier or excipient.
  • a pharmaceutical composition may comprise a combination of a miR-29a and a miR-29b mimics; a miR-29a and a miR-29c mimics; or a miR-29b and a miR-29c mimics.
  • the composition may comprise two mimics of the same microRNA.
  • the invention provides pharmaceutical compositions comprising a therapeutically effective amount of three microRNA mimetic compounds of the invention and a pharmaceutically acceptable carrier or excipient.
  • a pharmaceutical composition may comprise a combination of a miR-29a, a miR-29b and a miR-29c mimics.
  • the first and the second mimetic compounds or the first, second and the third mimetic compounds are present in equimolar concentrations.
  • Other mixing ratios such as about 1 :2, 1 :3, 1 :4, 1 :5, 1 :2: 1, 1 :3: 1, 1 :4: 1, 1 :2:3, 1 :2:4 are also envisioned for preparing pharmaceutical compositions comprising at least two of the miR- 29a, miR-29b, and miR-29c mimetic compounds.
  • one or more microRNA mimetic compounds of the invention may be administered concurrently but in separate compositions, with concurrently referring to mimetic compounds given within a short period, for instance, within about 5, 10, 20, or 30 minutes of each other.
  • miR-29a, miR-29b, and/or miR-29c mimetic compounds may be administered in separate compositions at different times.
  • the invention also encompasses embodiments where additional therapeutic agents may be administered along with miR-29a, miR-29b, and/or miR-29c mimetic compounds.
  • the additional therapeutic agent is a second anti-fibrotic agent.
  • the additional therapeutic agents may be administered concurrently but in separate formulations or sequentially.
  • additional therapeutic agents may be administered at different times prior to after administration of miR-29a, miR-29b, and/or miR-29c mimetic compounds.
  • pharmaceutical compositions will be prepared in a form appropriate for the intended application. Generally, this will entail preparing compositions that are essentially free of pyrogens, as well as other impurities that could be harmful to humans or animals.
  • Colloidal dispersion systems such as macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, liposomes and exosomes, may be used as delivery vehicles for miR-29a, miR-29b, and/or miR-29c mimetic compounds.
  • miR-29 mimics of the present invention may be formulated into liposome particles, which can then be aerosolized for inhaled delivery.
  • fat emulsions that are suitable for delivering the nucleic acids of the invention to target tissues include Intralipid®, Liposyn®, Liposyn® II, Liposyn® III, Nutrilipid, and other similar lipid emulsions.
  • a preferred colloidal system for use as a delivery vehicle in vivo is a liposome ⁇ i.e., an artificial membrane vesicle). The preparation and use of such systems is well known in the art.
  • liposomes used for delivery are amphoteric liposomes such SMARTICLES® (Marina Biotech, Inc.) which are described in detail in U.S. Pre-grant Publication No. 201 10076322.
  • SMARTICLES® Marina Biotech, Inc.
  • the surface charge on the SMARTICLES® is fully reversible which make them particularly suitable for the delivery of nucleic acids.
  • SMARTICLES® can be delivered via injection, remain stable, and aggregate free and cross cell membranes to deliver the nucleic acids.
  • Aqueous compositions of the present invention comprise an effective amount of the delivery vehicle comprising the miR-29 mimic (e.g. liposomes or other complexes) dissolved or dispersed in a pharmaceutically acceptable carrier or aqueous medium.
  • the phrases "pharmaceutically acceptable” or “pharmacologically acceptable” refers to molecular entities and compositions that do not produce adverse, allergic, or other untoward reactions when administered to an animal or a human.
  • pharmaceutically acceptable carrier includes solvents, buffers, solutions, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like acceptable for use in formulating pharmaceuticals, such as pharmaceuticals suitable for administration to humans.
  • the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredients of the present invention, its use in therapeutic compositions is contemplated. Supplementary active ingredients also can be incorporated into the compositions, provided they do not inactivate the polynucleotides of the compositions.
  • compositions of the invention are formulated for pulmonary, nasal, intranasal or ocular delivery and can be in the form of powders, aqueous solutions, aqueous aerosols, nasal drops, aerosols, and/or ocular drops.
  • Solid formulations for nasal/intranasal administration may contain excipients such as lactose or dextran.
  • Liquid formulations for nasal/intranasal administration may be aqueous or oily solutions for use in the form of aerosols, nasal drops or metered spray.
  • Formulations for pulmonary/nasal/intranasal administration may also include surfactants such as, for example, glycocholic acid, cholic acid, taurocholic acid, ethocholic acid, deoxycholic acid, chenodeoxycholic acid, dehydrocholic acid, glycodeoxycholic acid, salts of these acids, and cyclodextrins.
  • surfactants such as, for example, glycocholic acid, cholic acid, taurocholic acid, ethocholic acid, deoxycholic acid, chenodeoxycholic acid, dehydrocholic acid, glycodeoxycholic acid, salts of these acids, and cyclodextrins.
  • formulations for pulmonary/nasal/intranasal administration via inhalation include, but are not limited to a dry powder formulation, a liposomal formulation, a nano-suspension formulation, or a microsuspension formulation.
  • compositions for pulmonary/nasal/intranasal delivery are administered using an inhalation device.
  • inhalation device refers to any device that is capable of administering a miR-29 mimic composition to the respiratory airways of the subject.
  • Inhalation devices include devices such as metered dose inhalers (MDIs), dry powder inhalers (DPIs), jet nebulizers, ultrasonic wave nebulizers, heat vaporizers, soft mist inhalers, thermal aerosol inhalers, electrohydrodynamic-based solution misting inhaler.
  • Inhalation devices also include high efficiency nebulizers.
  • a nebulizer is a jet nebulizer, an ultrasonic nebulizer, a pulsating membrane nebulizer, a nebulizer comprising a vibrating mesh or plate with multiple apertures, a nebulizer comprising a vibration generator and an aqueous chamber, or a nebulizer that uses controlled device features to assist inspiratory flow of the aerosolized aqueous solution to the lungs of the subject.
  • Nebulizers, metered dose inhalers, and soft mist inhalers deliver pharmaceuticals by forming an aerosol which includes droplet sizes that can easily be inhaled.
  • a composition administered with a high efficiency nebulizer comprises one or more miR-29 mimics and pharmaceutically acceptable excipients or carriers such as purified water, mannitol, surfactants, and salts such as sodium chloride and sodium EDTA, etc.
  • the active compositions of the present invention may include classic pharmaceutical preparations. Administration of these compositions according to the present invention may be via any common route so long as the target tissue is available via that route. This includes oral, nasal (e.g. inhalational), ocular, or buccal. Alternatively, administration may be by intravenous, intradermal, subcutaneous, intraocular or intramuscular injection, or by direct injection into pulmonary or cardiac tissue. Pharmaceutical compositions comprising miRNA mimics may also be administered by catheter systems or systems that isolate coronary circulation for delivering therapeutic agents to the heart. Various catheter systems for delivering therapeutic agents to the heart and coronary vasculature are known in the art.
  • compositions comprising miR-29 mimics as described herein may be formulated as a coating for a medical device, such as a stent, balloon, or catheter.
  • a medical device such as a stent, balloon, or catheter.
  • the miR-29 mimics can be used to coat a metal stent to produce a drug-eluting stent.
  • a drug- eluting stent is a scaffold that holds open narrowed or diseased arteries and releases a compound to prevent cellular proliferation and/or inflammation.
  • the mimetic compounds may be applied to a metal stent imbedded in a thin polymer for release of the agonists or inhibitors over time.
  • the present invention includes a medical device, such as a balloon, catheter, or stent, coated with a miR- 29 mimic.
  • Sterile injectable solutions may be prepared by incorporating the active compounds in an appropriate amount into a solvent along with any other ingredients (for example as enumerated above) as desired, followed by filtered sterilization.
  • dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the desired other ingredients, e.g., as enumerated above.
  • compositions of the present invention generally may be formulated in a neutral or salt form.
  • Pharmaceutically-acceptable salts include, for example, acid addition salts (formed with the free amino groups of the protein) derived from inorganic acids ⁇ e.g., hydrochloric or phosphoric acids), or from organic acids ⁇ e.g., acetic, oxalic, tartaric, mandelic, and the like). Salts formed with the free carboxyl groups of the protein can also be derived from inorganic bases ⁇ e.g., sodium, potassium, ammonium, calcium, or ferric hydroxides) or from organic bases (e.g., isopropylamine, trimethylamine, histidine, procaine and the like).
  • solutions are preferably administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective.
  • the formulations may easily be administered in a variety of dosage forms such as injectable solutions, drug release capsules, drug-eluting stents or other coated vascular devices, and the like.
  • parenteral administration in an aqueous solution for example, the solution generally is suitably buffered and the liquid diluent first rendered isotonic for example with sufficient saline or glucose.
  • aqueous solutions may be used, for example, for intravenous, intramuscular, subcutaneous, intradermal, intraocular, and intraperitoneal administration.
  • Example 1 In vitro activity of miR-29 mimic
  • a miR-29b mimic containing SEQ ID NO: 2 as the first strand and SEQ ID NO: 1 as the second strand was transfected into a mouse fibroblast cell line (NIH 3T3) and the effect on Collagenlal (Collal) expression, a known direct target gene of miR-29 (van Rooij et al, 2008), was measured using qPCR.
  • Increasing amount of miR-29b mimic showed a dose-dependent decrease in Collal, compared to untreated, mock transfected (without any oligo) or non-targeting control (NTC) oligo treated cells, indicating the miR-29b mimic to be functional.
  • a siRNA directly targeting Collal was used as a positive control (FIG. IB).
  • Example 2 In vivo distribution, stability and clearance of miR-29 mimic
  • mice were injected intravenously with 10, 50, 100, or 125 mg per kg of the miR-29b mimic containing SEQ ID NO: 2 as the first strand and SEQ ID NO: 1 as the second strand and sacrificed four days later.
  • TRIzol® reagent solution of phenol and guanidine isothiocyaiiate
  • oligonucleotide probes were labeled with the Starfire Oligos Kit (IDT, Coralville, IA) and a- 32 P dATP (Amersham or Perkin Elmer). Probes were hybridized to the membranes overnight at 39°C in Rapid-hyb buffer (Amersham), after which they were washed twice for 10 minutes at 39°C with 0.5x SSC containing 0.1% SDS. The blots were exposed and quantified by Phosphorlmager analysis (GE HealthCare Life Sciences) and a U6 probe served as a loading control (ABI). The intensity of the radioactive signal was used to quantify the fold change in expression using a phosphorimager and ImageQuant (Bio-Rad).
  • Taqman MicroRNA assay (Applied Biosystems, ABI) was used to detect changes in miRNAs or genes according the manufacturer's recommendations, using 10-100 ng of total RNA.
  • U6 was used a control for miRNA analysis and GAPDH was used as a control for gene analysis.
  • 125 mpk of the miR-29b mimic was injected into mice and they were sacrificed 1, 2, 4, or 7 days later. Robust presence of miR-29b mimic could be detected by both Northern blot and real-time PCR analysis one day after injection in all tissues examined, however tissue clearance greatly differed thereafter (FIGS. IE and F). Liver and kidney rapidly cleared miR-29b mimic with minimal detection after day 1. Lung and spleen demonstrated the most pronounced detection of miR-29b mimic over time, which was sustained at least 4 days post-treatment (FIGS. IE and IF).
  • Example 3 miR-29b mimic blunts bleomycin-induced pulmonary fibrosis
  • control (saline- treated) and bleomycin-treated mice were injected with 100 mg per kg of the miR-29b mimiccontaining SEQ ID NO: 2 as the first strand and SEQ ID NO: 1 as the second strand, control mimic or a comparable volume of saline at two time-points: 3 and 10 days after bleomycin treatment; the animals were sacrificed and lungs harvested at day 14.
  • the miR-29b mimic was administered at days 10, 14 and 17 after bleomycin or saline and the mice were sacrificed at day 21. In both protocols, the lungs were harvested for histological analysis, hydroxyproline assay and RNA extraction.
  • miR-29 levels were reduced, while miR-29b mimic treatment resulted in the increased detection of miR-29b levels compared to either control or saline injected animals as measured by real-time PCR, albeit with a high level of variation (FIG. 2A).
  • sixteen lung tissue samples were obtained from surgical remnants of biopsies or lungs explanted from patients with idiopathic pulmonary fibrosis (IPF) who underwent pulmonary transplantation. Samples were obtained from University of Pittsburgh Health Sciences Tissue Bank. A comparable decline in miR-29 levels was observed in pulmonary biopsies of patients with idiopathic pulmonary fibrosis (IPF) compared to normal controls (FIG. 2B).
  • lung tissue sections (4 ⁇ ) were stained with Masson Trichrome (collagen/connective tissue), two slices per animal, two animals per group. Immune staining was performed after paraffin removal, hydration, and blocking, following the recommendation of the manufacturer (ABC detection system form Vector's lab, USA). Sections were incubated overnight at 4°C with the primary antibody (Igfl, diluted 1 : 100 in PBS) and during 1 hour at room temperature with the secondary antibodies (Invitrogen, USA). The sections were counterstained with hematoxylin. The primary antibody was replaced by nonimmune serum for negative controls. Finally, sections were mounted with mounting medium (DAKO, USA) and analyzed using a Nikon microscope. Histological analysis showed a clear and robust fibrotic and inflammatory response to bleomycin treatment, which was blunted by miR-29b mimic treatment (FIG. 2C).
  • lung hydroxyproline was analyzed for total collagen content with hydroxyproline colorimetric assay kit from Biovision (Milpitas, CA) following manufacturer's instruction. Briefly, the lungs from control and experimental mice were dried until constant weight and hydrolyzed in 12N HC1 for 3 hours at 120°C. The digestions reacted with Chloramine T reagent and visualized in DMAB reagent. The absorbance was measured at 560 nm in a microplate reader. Data are expressed as ⁇ g of hydroxypro line/right lung.
  • BAL bronchoalveolar lavage
  • samples were incubated for 30 min with streptavidin conjugated to R-phycoerythrin and analyzed in the Bio-Plex suspension array system (Bio-Rad).
  • Raw data was analyzed using Bioplex Manager software 6.0 (Bio-Rad).
  • the cytokine standards supplied by the manufacturer were used to calculate the concentrations of the samples.
  • the analytes that were below the detection range were not included in date interpretation. Also, samples that had a particular analyte below the detection range were excluded while calculating the median value.
  • miR-29b mimic or control was transfected into macrophage cells, RAW 264.7, and the cell supernatant was harvested at 24 and 48 hours after transfection.
  • IFN-r, IL- 1B, IL-2, IL-4, IL-5, IL-6, KC, IL-10, IL-12P70, and TNF-a were assessed, with no significant differences observed between miR-29b mimic and control (data not shown).
  • Tgfbl, Ctgf, FGF1, or PDGF expression a significant difference in CsO, Igfl, and Kc expression was observed (FIG.
  • miR-29 mimicry After establishing that early (day 3 and day 10) miR-29 mimicry was sufficient to prevent bleomycin induced fibrosis, the ability of miR-29 mimicry to affect established fibrosis was investigated. For that purpose, the miR-29b mimic administration was started at day 10 post bleomycin, and the doses were repeated at days 14 and 17, after which the lungs were harvested at day 21. Hydroxyproline assessment of the right lung showed a significant increase with bleomycin in both saline and control-treated lungs; however miR-29b mimic treatment blunted this effect (FIG. 4A). Furthermore, bleomycin treatment resulted in significant increases in Collal and CoBal expression, which was also normalized with miR- 29b mimic treatment (FIGS.
  • miR-29b mimic effects were assessed in vitro from different lung cells, including primary fibroblasts from IPF patients and A549 cells, a lung epithelial cell line. As expected, primary pulmonary fibroblasts from IPF patients show an increase in Collal and CoBal in response to TGF-a (FIGS. 4E and 4F). This effect was dose-dependently blunted with miR-29b mimic treatment at both 24 and 48 hours (FIGS. 4E, 4F and data not shown).
  • A549 cells respond to TGF-a with robust increases in Coll aland CoBal expression (FIGS. 4G and 4H).
  • miR-29b mimic treatment is able to block collagen induction, in both TGF-a treated as well as baseline conditions (FIGS. 4G and 4H).
  • the effects on collagen induction are much more robust in the A549 cells compared to primary IPF cells. However, this is likely due to the already high expression in primary fibroblasts from IPF patients.
  • miR-29 effects in the macrophage line, Thp-1 were also examined, but no collagen expression could be observed in the cells, regardless of stimulation (data not shown). These data suggest miR-29b mimicry is able to blunt collagen-induced expression in fibroblasts and epithelial cells.
  • the data described herein shows the feasibility of using microRNA mimics to restore the function of lost or down-regulated miRNAs.
  • RISC incorporation is required for appropriate miRNA function
  • careful design of the structural features of the synthetic oligonucleotide mimics is required.
  • the data in the present application shows that delivery to the appropriate cell type or tissue provides effective miRNA mimicry. For instance, in the case of pulmonary fibrosis, direct delivery through the inhaled route provides better treatment efficacy compared to traditional routes of administration.
  • miR-29 In addition to organ fibrosis, a number of studies have shown a role for miR-29 in dermal fibrosis such as in hypertrophic scars and keloids, and in cutaneous and other forms of systemic sclerosis (scleroderma). For example, fibroblasts and skin sections obtained from patients with systemic sclerosis showed a dramatic reduction in miR-29a levels compared to healthy controls (Maurer et al 2010). When overexpressed in systemic sclerosis fibroblasts, miR-29a was able to robustly reduce the expression of type I and III collagens, at both the RNA and protein level. Conversely, inhibition of miR-29 in normal fibroblasts resulted in an increase in these collagens.
  • miR-29 down-regulation is broadly applicable in multiple indications of fibrosis (Maurer et al 2010).
  • miR-29a transfection in healthy control dermal fibroblasts significantly down- regulated collagen expression.
  • miR-29a overexpression in dermal fibroblasts decreased secreted TIMP-1 and increased collagen gel degradation.
  • mice were anesthetized with 2-5% inhaled isofluorane using an inhalation chamber and were maintained under 1% isofluorane on a nose cone for all procedures.
  • Buprenorphine (0.1 mg/kg) was used as an analgesic for all surgical procedures.
  • Animals were anesthetized, depilated by shaving and administration of Nair hair removal cream, and the skin site was prepared for incision by betadine and alcohol surgical scrub. One to two 1 cm long skin incisions were made on the backs of the mice.
  • Incisions were closed with 2-5 interrupted sutures and were covered with Tegaderm transparent semi-occlusive dressing (3M).
  • Mice with or without incisional skin wounds were treated with intradermal injection with vehicle (PBS), 100 nmol miR-29b mimic (comprising SEQ ID NO: 2 as the first strand and SEQ ID NO: 1 as the second strand) or 100 nmol antimiR-29, 3 days after incisional wound creation, by intradermal injection of oligonucleotide compounds or vehicle (PBS) in two 50 volumes located on either side of the incision midline, or by injection of a single 100 volume into adjacent, unwounded skin.
  • PBS vehicle
  • PBS oligonucleotide compounds or vehicle
  • the antimiR-29 has the sequence of 5'- lGs.dAs.dTs.dTs.lTs.lCs.dAs.lAs.dAs.lTs.lGs.dGs.lTs.dGs.lCs.lTs-3' (SEQ ID NO: 36) where "1" represents a locked nucleotide, "d” represents a deoxyribonucleotides and "s” represents a phosphorothioate linkage. Mice were sacrificed 24 hours after administration of oligonucleotide compounds and skin at the treatment site(s) was harvested and snap frozen in liquid nitrogen for analysis of mRNA expression.
  • RNA per sample was sent to MOgene for microarray analysis as compared to a mouse universal reference RNA (Agilent) on an Agilent array (Mouse GE (V2), 4x44k - 026655). Analysis was performed using ArrayStudio and heatmaps were generated using the R software program.
  • Rab39 -1.30 0.018 1.61 0.001 miR-29b mimic antimiR-29
  • Faml20a 1.09 0.043 -1.10 0.0320027C24Rik 1.10 0.032 -1.15 0.005
  • Vprbp 1.10 0.042 -1.38 0.000
  • Mrps27 1.16 0.015 -1.22 0.003
  • Trnaulap 1.16 0.007 -1.18 0.004
  • Map3k3 1.19 0.030 -1.28 0.005
  • Nopl4 1.20 0.003 -1.48 0.000
  • Nopl6 1.20 0.038 -1.22 0.030
  • Epb4.1l5 1.21 0.049 -1.38 0.004
  • mice with acute incisional wounds were treated with intradermal injection of PBS, 20, 50, or 100 nmol of miR-29b mimic (comprising SEQ ID NO: 2 as the first strand and SEQ ID NO: 1 as the second strand).
  • miR-29b mimic comprising SEQ ID NO: 2 as the first strand and SEQ ID NO: 1 as the second strand.
  • Quantitative reverse-transcriptase PCR analysis was performed on 24 genes identified as being direct or indirect targets of miR-29 modulation in the skin (19 repressed by miR-29b mimic and upregulated by antimiR-29, 5 upregulated by miR-29b mimic and repressed by antimiR-29).
  • Extracellular matrix genes (collagens, ELN, etc.) and others involved in the fibrotic process (e.g. MMP2, TGFB2) were shown to be repressed by miR- 29b mimic treatment in the skin (FIG. 11 A), whereas selected cell surface receptors (ITGA3, LBR, NUMB, SDC4) and factors associated with receptor endocytosis (SNX27) were shown to be increased with miR-29b mimic treatment in the skin (FIG. 1 IB). These studies indicate that the miR-29b mimic is active when treated locally in the skin, and suggests that in addition to its effect on organ fibrosis, miR-29 mimicry could be an effective therapy for cutaneous fibrosis of various etiologies.
  • miR-29b mimic is active when treated locally in the skin, and suggests that in addition to its effect on organ fibrosis, miR-29 mimicry could be an effective therapy for cutaneous fibrosis of various etiologies.
  • miR-29a, b, and c mimics were transfected into IMR-90 human lung fibroblasts at a concentration of lOnM, and collagen expression was measured by quantitative RT-PCR.
  • a checkerboard pattern of 2' O-Methyl modifications makes miR-29 mimics (a mimic comprising SEQ ID NO: 31 as the first strand and SEQ ID NO: 28 as the second strand and a mimic comprising SEQ ID NO: 32 as the first strand and SEQ ID NO: 29 as the second strand) completely ineffective.
  • Modifications of all C and U residues on the antisense (first/guide) strand (a mimic comprising SEQ ID NO: 33 as the first strand and SEQ ID NO: 1 as the second strand) partially reduces the mimic activity.
  • removal of the 3 ' overhang on the antisense strand partially reduces the mimic activity. See Figure 12.
  • miR-29b mimic comprising SEQ ID NO: 19 as the first strand and SEQ ID NO: 1 as the second strand and the mimic comprising SEQ ID NO: 19 as the first strand and SEQ ID NO: 15 as the second strand.
  • miR-29b mimics containing a nine carbon linker (SEQ ID NO: 19/SEQ ID NO: 17) and a linker at the 5' end (SEQ ID NO: 19/SEQ ID NO: 16) were not effective in repressing target genes (FIG. 13).
  • RAB-9 skin fibroblast cells (ATCC CRL-1414) were transfected with varying concentrations of miR-29b mimics with (the mimic containing SEQ ID NO: 2 as the first strand and SEQ ID NO: 1 as the second strand) and without (the mimic containing SEQ ID NO: 19 as the first strand and SEQ ID NO: 1 as the second strand) 5' phosphorylation on the antisense strand.
  • No significant differences in target gene repression as measured by Collal, Colla2 or CoBal expression was observed in the activity of the two mimics (represented as N/S in FIG. 14).
  • Both miR-29b mimics significantly (p ⁇ 0.0001) repressed the expression of target genes compared to vehicle, mock transfection or control mimic treatment. See FIG. 14.
  • TGF- beta/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. Journal of the American Society of Nephrology : JASN 22: 1462-1474

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

La présente invention concerne des mimétiques d'oligonucléotides synthétiques des ARNmi. En particulier, la présente invention concerne des mimétiques d'oligonucléotides de miR-29 à double brin chimiquement modifiées. L'invention concerne également des compositions pharmaceutiques comprenant les mimétiques et leur utilisation dans le traitement ou la prévention de états associés au dérèglement de gènes de matrice extracellulaire, tels que des états fibreux du tissu.
PCT/US2015/049018 2014-09-08 2015-09-08 Mimetiques de mir-29 et leurs utilisations Ceased WO2016040373A1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA2960387A CA2960387A1 (fr) 2014-09-08 2015-09-08 Mimetiques de mir-29 et leurs utilisations
KR1020177008019A KR20170068452A (ko) 2014-09-08 2015-09-08 Mir-29 모방체 및 이의 용도
BR112017004648A BR112017004648A2 (pt) 2014-09-08 2015-09-08 simuladores mir-29 e os usos deste
RU2017111775A RU2712511C2 (ru) 2014-09-08 2015-09-08 Миметики mir-29 и пути их применения
EP15840320.4A EP3201213B1 (fr) 2014-09-08 2015-09-08 Mimetiques de mir-29 et leurs utilisations
AU2015315298A AU2015315298B2 (en) 2014-09-08 2015-09-08 miR-29 mimics and uses thereof
JP2017513109A JP6837963B2 (ja) 2014-09-08 2015-09-08 Ｍｉｒ−２９模倣物およびその使用
MX2017003018A MX382425B (es) 2014-09-08 2015-09-08 Imitadores de mir-29 y usos de los mismos
CN201580057333.0A CN107108685B (zh) 2014-09-08 2015-09-08 miR-29模拟物及其用途
IL250952A IL250952A0 (en) 2014-09-08 2017-03-06 Mir-29 mimics and uses thereof
PH12017500424A PH12017500424A1 (en) 2014-09-08 2017-03-07 Mir-29 mimics and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462047562P 2014-09-08 2014-09-08
US62/047,562 2014-09-08

Publications (1)

Publication Number Publication Date
WO2016040373A1 true WO2016040373A1 (fr) 2016-03-17

Family

ID=55436959

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/049018 Ceased WO2016040373A1 (fr) 2014-09-08 2015-09-08 Mimetiques de mir-29 et leurs utilisations

Country Status (14)

Country Link
US (3) US9376681B2 (fr)
EP (1) EP3201213B1 (fr)
JP (1) JP6837963B2 (fr)
KR (1) KR20170068452A (fr)
CN (1) CN107108685B (fr)
AU (1) AU2015315298B2 (fr)
BR (1) BR112017004648A2 (fr)
CA (1) CA2960387A1 (fr)
CL (1) CL2017000564A1 (fr)
IL (1) IL250952A0 (fr)
MX (1) MX382425B (fr)
PH (1) PH12017500424A1 (fr)
RU (1) RU2712511C2 (fr)
WO (1) WO2016040373A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9719088B2 (en) 2007-07-31 2017-08-01 The Board Of Regents, The University Of Texas System Micro-RNA family that modulates fibrosis and uses thereof
US9932582B2 (en) 2014-01-14 2018-04-03 The University Court Of The University Of Glasgow Materials and methods for modulation of tendon healing
US9994847B2 (en) 2014-09-08 2018-06-12 MiRagen Therapeutics, Inc. miR-29 mimics and uses thereof
CN111249466A (zh) * 2020-03-14 2020-06-09 浙江大学医学院附属第一医院 丹参酮ⅡA与miR-29b抑制剂联合在制备治疗肌腱粘连的药物中的应用
WO2022084561A3 (fr) * 2020-10-23 2022-06-02 Causeway Therapeutics Limited Composés de microarn-29, compositions et utilisations thérapeutiques
EP4035659A1 (fr) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosomes destinés à l'administration d'agents thérapeutiques
WO2024223065A1 (fr) * 2023-04-28 2024-10-31 Causeway Therapeutics Limited Composés de microarn-29, compositions et utilisations en thérapie, et procédés d'évaluation de lésions tendinopathiques
EP4114938A4 (fr) * 2020-03-04 2025-02-19 The Trustees of Indiana University Procédés de re-engagement d'une voie de cicatrisation de plaie f?tale pour la réparation de la peau d'un adulte

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10801025B2 (en) 2016-07-26 2020-10-13 Indiana University Research And Technology Corporation MicroRNA therapy for pancreatic cancer
CN107982536B (zh) * 2017-10-27 2021-04-09 上海交通大学医学院附属第九人民医院 一种药物作用靶点的组合物和应用
US20200376019A1 (en) * 2017-11-30 2020-12-03 MiRagen Therapeutics, Inc. miR29 MIMICS FOR THE TREATMENT OF OCULAR FIBROSIS
US11021712B1 (en) 2018-09-07 2021-06-01 Washington University MiRNA mimics and uses thereof
CN109234381B (zh) * 2018-10-22 2021-06-18 云南省玉溪市人民医院 miR-2682-5p作为肾纤维化标志物的应用
WO2020181107A1 (fr) * 2019-03-05 2020-09-10 MiRagen Therapeutics, Inc. Mimetiques de microarn et leurs utilisations
WO2020181130A2 (fr) * 2019-03-05 2020-09-10 MiRagen Therapeutics, Inc. Conjugués de polynucléotides et leurs utilisations
US11607428B2 (en) 2019-06-06 2023-03-21 Spiritus Therapeutics, Inc. Mesenchymal stem cell-derived extracellular vesicles and uses thereof for treating and diagnosing fibrotic diseases
WO2020247675A1 (fr) * 2019-06-06 2020-12-10 Spiritus Therapeutics, Inc. Procédés pour atténuer une infection virale et pour traiter une lésion pulmonaire
US12097222B2 (en) 2019-06-06 2024-09-24 Spiritus Therapeutics, Inc. Methods for attenuating viral infection and for treating lung injury
CN111449025A (zh) * 2020-04-02 2020-07-28 华北理工大学 miRNAs在抑制大鼠肝纤维化中的应用
US11987793B2 (en) 2020-05-03 2024-05-21 Washington University Compositions and methods for prevention of bladder fibrosis
CN111647656A (zh) * 2020-05-15 2020-09-11 华中科技大学同济医学院附属同济医院 mir-29a基因在检测肝癌及肝纤维化中的应用及所述基因条件敲入小鼠的构建方法
CN112226436B (zh) * 2020-10-20 2021-05-18 南京医科大学 MiR-29海绵、包含miR-29海绵的核酸构建体及其应用
CN117813099A (zh) * 2021-08-06 2024-04-02 领康冠军有限公司 基于miRNA的组合物及其使用方法

Citations (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783565A (en) 1994-12-09 1998-07-21 Genzyme Corporation Cationic amphiphiles containing spermine or spermidine cationic group for intracellular delivery of therapeutic molecules
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
US6416510B1 (en) 1997-03-13 2002-07-09 Biocardia, Inc. Drug delivery catheters that attach to tissue and methods for their use
US6589286B1 (en) 2001-09-12 2003-07-08 Jason Litner Eustachian tube stent
WO2003093449A2 (fr) 2002-05-06 2003-11-13 Nucleonics, Inc. Procedes d'administration d'acides nucleiques
WO2004004602A1 (fr) 2002-07-08 2004-01-15 Abbott Laboratories Vascular Enterprises Limited Endoprothese d'elution de medicament et procedes pour la produire
US6693187B1 (en) 2000-10-17 2004-02-17 Lievre Cornu Llc Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
US6716196B2 (en) 1993-07-30 2004-04-06 The Regents Of The University Of California Catheter system for delivery of Therapeutic compounds to cardiac tissue
US6716242B1 (en) 1999-10-13 2004-04-06 Peter A. Altman Pulmonary vein stent and method for use
US6747014B2 (en) 1997-07-01 2004-06-08 Isis Pharmaceuticals, Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
US20050059005A1 (en) * 2001-09-28 2005-03-17 Thomas Tuschl Microrna molecules
WO2005082440A1 (fr) 2004-02-26 2005-09-09 V-Kardia Pty Ltd Isolement de circulation cardiaque
US6953466B2 (en) 1997-11-04 2005-10-11 Boston Scientific Scimed, Inc. Methods for delivering a therapeutic implant to tissue
US7041127B2 (en) 2003-05-28 2006-05-09 Ledergerber Walter J Textured and drug eluting coronary artery stent
US7055237B2 (en) 2003-09-29 2006-06-06 Medtronic Vascular, Inc. Method of forming a drug eluting stent
US20060148742A1 (en) 2004-02-26 2006-07-06 Kaye David M Polynucleotide delivery to cardiac tissue
US7083642B2 (en) 2000-12-22 2006-08-01 Avantec Vascular Corporation Delivery of therapeutic capable agents
US7087263B2 (en) 2002-10-09 2006-08-08 Advanced Cardiovascular Systems, Inc. Rare limiting barriers for implantable medical devices
US7105018B1 (en) 2002-12-30 2006-09-12 Advanced Cardiovascular Systems, Inc. Drug-eluting stent cover and method of use
US7144422B1 (en) 2002-11-13 2006-12-05 Advanced Cardiovascular Systems, Inc. Drug-eluting stent and methods of making the same
US7156869B1 (en) 2003-01-27 2007-01-02 Advanced Cardiovascular Systems, Inc. Drug-eluting stent and delivery system with tapered stent in shoulder region
US20070060907A1 (en) 2004-02-26 2007-03-15 Shapland James E Regional cardiac tissue treatment
US7232573B1 (en) 2002-09-26 2007-06-19 Advanced Cardiovascular Systems, Inc. Stent coatings containing self-assembled monolayers
US7236821B2 (en) 2002-02-19 2007-06-26 Cardiac Pacemakers, Inc. Chronically-implanted device for sensing and therapy
US7247313B2 (en) 2001-06-27 2007-07-24 Advanced Cardiovascular Systems, Inc. Polyacrylates coatings for implantable medical devices
US20070203445A1 (en) 2004-02-26 2007-08-30 V-Kardia Pty Ltd Isolating cardiac circulation
US7294329B1 (en) 2002-07-18 2007-11-13 Advanced Cardiovascular Systems, Inc. Poly(vinyl acetal) coatings for implantable medical devices
WO2009018493A1 (fr) 2007-07-31 2009-02-05 The Board Of Regents Of The University Of Texas System Famille de micro-arn modulant une fibrose et procédés d'utilisation associés
US20100184209A1 (en) * 2006-02-17 2010-07-22 Dharmacon, Inc. Compositions and methods for inhibiting gene silencing by rna interference
US20110076322A1 (en) 2005-09-15 2011-03-31 Steffen Panzner Amphoteric liposomes
US20120022143A1 (en) * 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA)
US20120128761A1 (en) 2009-05-05 2012-05-24 MiRagen Therapeutics, Inc. Lipophilic Polynucleotide Conjugates
WO2013032962A2 (fr) 2011-08-28 2013-03-07 The Board Of Trustees Of The Leland Stanford Junior University Microarn pour traiter un accident vasculaire cérébral, une lésion cérébrale ischémique, une lésion cérébrale traumatique et une maladie neurodégénérative

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2533701A1 (fr) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Composes oligomeres et compositions utilisables pour moduler des petits arn non-codants
US20070213292A1 (en) * 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
AU2007211082B2 (en) 2006-01-27 2012-09-27 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of microRNAs
WO2008036841A2 (fr) * 2006-09-22 2008-03-27 Dharmacon, Inc. Complexes d'oligonucléotides tripartites et procédés de silençage de gènes par interférence arn
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
EP2096171A1 (fr) * 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg Cibles microARN (miARN) et en aval à des fins de diagnostic et thérapeutiques
KR20110082515A (ko) 2008-09-04 2011-07-19 유니베르시태트 취리히 피부 경화증의 치료
WO2010039502A2 (fr) 2008-09-23 2010-04-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Microarn afférents à la fibrose pulmonaire idiopathique
JP2011004708A (ja) * 2009-06-29 2011-01-13 Univ Of Tokyo ｓｍａｌｌＲＮＡ二本鎖およびヘアピン型ＲＮＡの設計方法
US9096850B2 (en) 2009-08-24 2015-08-04 Sirna Therapeutics, Inc. Segmented micro RNA mimetics
EP2371370A1 (fr) * 2010-04-01 2011-10-05 Johann Wolfgang Goethe-Universität Frankfurt am Main Antagonistes de l'expression de miARN-29 et leur utilisation dans la prévention et le traitement des anévrismes aortiques et déstabilisation de plaque athérosclérotique
US9914972B2 (en) * 2011-03-28 2018-03-13 Rosetta Genomics Ltd. Methods for lung cancer classification
CA2832899A1 (fr) * 2011-04-12 2012-10-18 Beth Israel Deaconess Medical Center, Inc. Inhibiteurs de micro-arn et leurs utilisations dans des maladies
HK1201299A1 (en) 2011-11-22 2015-08-28 Intermune, Inc. Methods of diagnosing and treating idiopathic pulmonary fibrosis
GB201400598D0 (en) * 2014-01-14 2014-03-05 Univ Glasgow Materials and methods for modulation of tendon healing
WO2015133521A1 (fr) 2014-03-04 2015-09-11 浩文 山本 Nouvelle séquence d'arn possédant une activité anti-tumorale
WO2016040373A1 (fr) 2014-09-08 2016-03-17 MiRagen Therapeutics, Inc. Mimetiques de mir-29 et leurs utilisations

Patent Citations (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US6716196B2 (en) 1993-07-30 2004-04-06 The Regents Of The University Of California Catheter system for delivery of Therapeutic compounds to cardiac tissue
US7202227B2 (en) 1994-09-28 2007-04-10 Wyeth Multifunctional molecular complexes for gene transfer to cells
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US6127170A (en) 1994-09-28 2000-10-03 American Home Products Corporation Multifunctional complexes for gene transfer into cells comprising a nucleic acid bound to a polyamine and having a endosome disruption agent
US6379965B1 (en) 1994-09-28 2002-04-30 American Home Products Corporation Multifunctional complexes for gene transfer into cells comprising a nucleic acid bound to a polyamine and having an endosome disruption agent
US5783565A (en) 1994-12-09 1998-07-21 Genzyme Corporation Cationic amphiphiles containing spermine or spermidine cationic group for intracellular delivery of therapeutic molecules
US6416510B1 (en) 1997-03-13 2002-07-09 Biocardia, Inc. Drug delivery catheters that attach to tissue and methods for their use
US6383512B1 (en) 1997-04-30 2002-05-07 American Home Products Corporation Vesicular complexes and methods of making and using the same
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
US6747014B2 (en) 1997-07-01 2004-06-08 Isis Pharmaceuticals, Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
US6953466B2 (en) 1997-11-04 2005-10-11 Boston Scientific Scimed, Inc. Methods for delivering a therapeutic implant to tissue
US6716242B1 (en) 1999-10-13 2004-04-06 Peter A. Altman Pulmonary vein stent and method for use
US7067641B2 (en) 2000-10-17 2006-06-27 Lievre Cornu Llc Phosphinoamidite carboxylates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
US6693187B1 (en) 2000-10-17 2004-02-17 Lievre Cornu Llc Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
US7083642B2 (en) 2000-12-22 2006-08-01 Avantec Vascular Corporation Delivery of therapeutic capable agents
US7247313B2 (en) 2001-06-27 2007-07-24 Advanced Cardiovascular Systems, Inc. Polyacrylates coatings for implantable medical devices
US6589286B1 (en) 2001-09-12 2003-07-08 Jason Litner Eustachian tube stent
US20050059005A1 (en) * 2001-09-28 2005-03-17 Thomas Tuschl Microrna molecules
US7236821B2 (en) 2002-02-19 2007-06-26 Cardiac Pacemakers, Inc. Chronically-implanted device for sensing and therapy
WO2003093449A2 (fr) 2002-05-06 2003-11-13 Nucleonics, Inc. Procedes d'administration d'acides nucleiques
WO2004004602A1 (fr) 2002-07-08 2004-01-15 Abbott Laboratories Vascular Enterprises Limited Endoprothese d'elution de medicament et procedes pour la produire
US7294329B1 (en) 2002-07-18 2007-11-13 Advanced Cardiovascular Systems, Inc. Poly(vinyl acetal) coatings for implantable medical devices
US7232573B1 (en) 2002-09-26 2007-06-19 Advanced Cardiovascular Systems, Inc. Stent coatings containing self-assembled monolayers
US7087263B2 (en) 2002-10-09 2006-08-08 Advanced Cardiovascular Systems, Inc. Rare limiting barriers for implantable medical devices
US7144422B1 (en) 2002-11-13 2006-12-05 Advanced Cardiovascular Systems, Inc. Drug-eluting stent and methods of making the same
US7105018B1 (en) 2002-12-30 2006-09-12 Advanced Cardiovascular Systems, Inc. Drug-eluting stent cover and method of use
US7156869B1 (en) 2003-01-27 2007-01-02 Advanced Cardiovascular Systems, Inc. Drug-eluting stent and delivery system with tapered stent in shoulder region
US7041127B2 (en) 2003-05-28 2006-05-09 Ledergerber Walter J Textured and drug eluting coronary artery stent
US7273493B2 (en) 2003-05-28 2007-09-25 Ledergerber Walter J Methods for forming and fabricating textured and drug eluting coronary artery stent
US7055237B2 (en) 2003-09-29 2006-06-06 Medtronic Vascular, Inc. Method of forming a drug eluting stent
US20070060907A1 (en) 2004-02-26 2007-03-15 Shapland James E Regional cardiac tissue treatment
WO2005082440A1 (fr) 2004-02-26 2005-09-09 V-Kardia Pty Ltd Isolement de circulation cardiaque
US20060148742A1 (en) 2004-02-26 2006-07-06 Kaye David M Polynucleotide delivery to cardiac tissue
US20070203445A1 (en) 2004-02-26 2007-08-30 V-Kardia Pty Ltd Isolating cardiac circulation
WO2006089340A2 (fr) 2005-02-23 2006-08-31 V-Kardia Pty Ltd Administration d'un polynucleotide a un tissu cardiaque
US20110076322A1 (en) 2005-09-15 2011-03-31 Steffen Panzner Amphoteric liposomes
US20100184209A1 (en) * 2006-02-17 2010-07-22 Dharmacon, Inc. Compositions and methods for inhibiting gene silencing by rna interference
WO2009018493A1 (fr) 2007-07-31 2009-02-05 The Board Of Regents Of The University Of Texas System Famille de micro-arn modulant une fibrose et procédés d'utilisation associés
US8440636B2 (en) 2007-07-31 2013-05-14 The Board Of Regents, The University Of Texas System Micro-RNA family that modulates fibrosis and uses thereof
US20130261169A1 (en) 2007-07-31 2013-10-03 The Board Of Regents, The University Of Texas System Micro-RNA Family That Modulates Fibrosis and Uses Thereof
US20120022143A1 (en) * 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA)
US20120128761A1 (en) 2009-05-05 2012-05-24 MiRagen Therapeutics, Inc. Lipophilic Polynucleotide Conjugates
WO2013032962A2 (fr) 2011-08-28 2013-03-07 The Board Of Trustees Of The Leland Stanford Junior University Microarn pour traiter un accident vasculaire cérébral, une lésion cérébrale ischémique, une lésion cérébrale traumatique et une maladie neurodégénérative

Non-Patent Citations (27)

* Cited by examiner, † Cited by third party
Title
BOUCHIE A: "First microRNA mimic enters clinic", NATURE BIOTECHNOLOGY, vol. 31, 2013, pages 577
CUSHING LKUANG PPQIAN JSHAO FWU JLITTLE FTHANNICKAL VJCARDOSO WVLU J: "miR-29 is a major regulator of genes associated with pulmonary fibrosis", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, vol. 45, 2011, pages 287 - 294, XP055267289, doi:10.1165/rcmb.2010-0323OC
FRIEDMAN SLSHEPPARD DDUFFIELD JSVIOLETTE S: "Therapy for fibrotic diseases: nearing the starting line", SCI TRANSL MED, vol. 5, 2013, pages 167srl61
HE YHUANG CLIN XLI J: "MicroRNA-29 family, a crucial therapeutic target for fibrosis diseases", BIOCHIMIE, vol. 95, 2013, pages 1355 - 1359, XP028556852, doi:10.1016/j.biochi.2013.03.010
JANSSEN HLREESINK HWLAWITZ EJZEUZEM SRODRIGUEZ-TORRES MPATEL KVAN DER MEER AJPATICK AKCHEN AZHOU Y: "Treatment of HCV infection by targeting microRNA", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 368, 2013, pages 1685 - 1694, XP055227943, doi:10.1056/NEJMoa1209026
KASINSKI ALSLACK FJ: "miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma", CANCER RES, vol. 72, 2012, pages 5576 - 5587
KOTA JCHIVUKULA RRO'DONNELL KAWENTZEL EAMONTGOMERY CLHWANG HWCHANG TCVIVEKANANDAN PTORBENSON MCLARK KR: "Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model", CELL, vol. 137, 2009, pages 1005 - 1017, XP055004118, doi:10.1016/j.cell.2009.04.021
MAURER BSTANCZYK JJUNGEL AAKHMETSHINA ATRENKMANN MBROCK MKOWAL-BIELECKA OGAY REMICHEL BADISTLER JH: "MicroRNA-29, a key regulator of collagen expression in systemic sclerosis", ARTHRITIS AND RHEUMATISM, vol. 62, 2010, pages 1733 - 1743, XP055088563, doi:10.1002/art.27443
MIYAZAKI YADACHI HKATSUNO MMINAMIYAMA MJIANG YMHUANG ZDOI HMATSUMOTO SKONDO NIIDA M: "Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2", NATURE MEDICINE, 2012
MONTGOMERY ET AL.: "MicroRNA mimicry blocks pulmonary fibrosis", EMBO MOLECULAR MEDICINE, vol. 6, 19 September 2014 (2014-09-19), pages 1347 - 1356, XP055185402, DOI: doi:10.15252/emmm.201303604 *
PANDIT KVCORCORAN DYOUSEF HYARLAGADDA MTZOUVELEKIS AGIBSON KFKONISHI KYOUSEM SASINGH MHANDLEY D: "Inhibition and role of let-7d in idiopathic pulmonary fibrosis", AM JRESPIR CRIT CARE MED, vol. 182, 2010, pages 220 - 229, XP055031319, doi:10.1164/rccm.200911-1698OC
PANDIT KVMILOSEVIC JKAMINSKI N: "MicroRNAs in idiopathic pulmonary fibrosis", TRANSL RES, vol. 157, 2011, pages 191 - 199, XP028368080, doi:10.1016/j.trsl.2011.01.012
PEACOCK HKANNAN ABEAL PABURROWS CJ: "Chemical modification of siRNA bases to probe and enhance RNA interference", THE JOURNAL OF ORGANIC CHEMISTRY, vol. 76, 2011, pages 7295 - 7300, XP055087444, doi:10.1021/jo2012225
QIN WCHUNG ACHUANG XRMENG XMHUI DSYU CMSUNG JJLAN HY: "TGF-beta/Smad3 signaling promotes renal fibrosis by inhibiting miR-29", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY : JASN, vol. 22, 2011, pages 1462 - 1474, XP055454665, doi:10.1681/ASN.2010121308
RODERBURG CURBAN GWBETTERMANN KVUCUR MZIMMERMANN HSCHMIDT SJANSSEN JKOPPE CKNOLLE PCASTOLDI M: "Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis", HEPATOLOGY, vol. 53, 2011, pages 209 - 218, XP055185058, doi:10.1002/hep.23922
SARMISTHA BANYOPADHYAY ET AL., JOURNAL OF INFECTIOUS DISEASES, vol. 203, no. 12, June 2011 (2011-06-01)
See also references of EP3201213A4
SEKIYA YOGAWA TYOSHIZATO KIKEDA KKAWADA N: "Suppression of hepatic stellate cell activation by microRNA-29b", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 412, 2011, pages 74 - 79, XP028382710, doi:10.1016/j.bbrc.2011.07.041
VAN ROOIJ EOLSON EN: "MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles", NATURE REVIEWS DRUG DISCOVERY, vol. 11, 2012, pages 860 - 872
VAN ROOIJ EPURCELL ALLEVIN AA: "Developing microRNA therapeutics", CIRC RES, vol. 110, 2012, pages 496 - 507, XP055144403, doi:10.1161/CIRCRESAHA.111.247916
VAN ROOIJ ESUTHERLAND LBTHATCHER JEDIMAIO JMNASEEM RHMARSHALL WSHILL JAOLSON EN: "Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis", PROC NATL ACAD SCI USA, vol. 105, 2008, pages 13027 - 13032, XP002571306, doi:10.1073/pnas.0805038105
VAN ROOIJ ET AL.: "Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 105, 2 September 2008 (2008-09-02), pages 13027 - 13032, XP055417593, DOI: doi:10.1073/pnas.0805038105 *
WANG BKOMERS RCAREW RWINBANKS CEXU BHERMAN-EDELSTEIN MKOH PTHOMAS MJANDELEIT-DAHM KGREGOREVIC P: "Suppression of microRNA-29 expression by TGF-betal promotes collagen expression and renal fibrosis", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY : JASN, vol. 23, 2012, pages 252 - 265
XIAO JMENG XMHUANG XRCHUNG ACFENG YLHUI DSYU CMSUNG JJLAN HY: "miR-29 inhibits bleomycin-induced pulmonary fibrosis in mice", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, vol. 20, 2012, pages 1251 - 1260, XP055454640, doi:10.1038/mt.2012.36
YANG ZHANG ET AL., THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, vol. 22, no. 5, May 2014 (2014-05-01)
YE ET AL.: "Downregulation of microRNA-29 by antisense inhibitors and a PPAR-γ agonist protects against myocardial ischaemia-reperfusion injury", CARDIOVASCULAR RESEARCH, vol. 87, 17 February 2010 (2010-02-17), pages 535 - 544, XP055417599 *
ZHANG YWU LWANG YZHANG MLI LZHU DLI XGU HZHANG CYZEN K: "Protective role of estrogen-induced miRNA-29 expression in carbon tetrachloride-induced mouse liver injury", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 287, 2012, pages 14851 - 14862

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9719088B2 (en) 2007-07-31 2017-08-01 The Board Of Regents, The University Of Texas System Micro-RNA family that modulates fibrosis and uses thereof
US9719086B2 (en) 2007-07-31 2017-08-01 The Board Of Regents, The University Of Texas System Micro-RNA family that modulates fibrosis and uses thereof
US10392618B2 (en) 2007-07-31 2019-08-27 The Board Of Regents, The University Of Texas System Micro-RNA family that modulates extracellular matrix genes and uses thereof
US9932582B2 (en) 2014-01-14 2018-04-03 The University Court Of The University Of Glasgow Materials and methods for modulation of tendon healing
US10472631B2 (en) 2014-01-14 2019-11-12 The University Court Of The University Of Glasgow Materials and methods for modulation of tendon healing
US9994847B2 (en) 2014-09-08 2018-06-12 MiRagen Therapeutics, Inc. miR-29 mimics and uses thereof
EP4035659A1 (fr) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosomes destinés à l'administration d'agents thérapeutiques
EP4114938A4 (fr) * 2020-03-04 2025-02-19 The Trustees of Indiana University Procédés de re-engagement d'une voie de cicatrisation de plaie f?tale pour la réparation de la peau d'un adulte
CN111249466A (zh) * 2020-03-14 2020-06-09 浙江大学医学院附属第一医院 丹参酮ⅡA与miR-29b抑制剂联合在制备治疗肌腱粘连的药物中的应用
CN111249466B (zh) * 2020-03-14 2022-04-15 浙江大学医学院附属第一医院 丹参酮ⅡA与miR-29b抑制剂联合在制备治疗肌腱粘连的药物中的应用
WO2022084561A3 (fr) * 2020-10-23 2022-06-02 Causeway Therapeutics Limited Composés de microarn-29, compositions et utilisations thérapeutiques
WO2024223065A1 (fr) * 2023-04-28 2024-10-31 Causeway Therapeutics Limited Composés de microarn-29, compositions et utilisations en thérapie, et procédés d'évaluation de lésions tendinopathiques

Also Published As

Publication number Publication date
AU2015315298B2 (en) 2020-05-14
RU2017111775A3 (fr) 2019-03-14
RU2017111775A (ru) 2018-10-10
PH12017500424B1 (en) 2017-07-17
BR112017004648A2 (pt) 2018-05-08
CA2960387A1 (fr) 2016-03-17
JP2017527294A (ja) 2017-09-21
IL250952A0 (en) 2017-04-30
RU2712511C2 (ru) 2020-01-29
CL2017000564A1 (es) 2018-05-04
KR20170068452A (ko) 2017-06-19
EP3201213A1 (fr) 2017-08-09
CN107108685B (zh) 2020-10-20
AU2015315298A1 (en) 2017-03-30
MX382425B (es) 2025-03-13
US20190127734A1 (en) 2019-05-02
US20160068842A1 (en) 2016-03-10
MX2017003018A (es) 2018-01-24
EP3201213A4 (fr) 2018-07-25
US9994847B2 (en) 2018-06-12
EP3201213B1 (fr) 2021-06-02
JP6837963B2 (ja) 2021-03-03
CN107108685A (zh) 2017-08-29
PH12017500424A1 (en) 2017-07-17
US20160355815A1 (en) 2016-12-08
US9376681B2 (en) 2016-06-28

Similar Documents

Publication Publication Date Title
AU2015315298B2 (en) miR-29 mimics and uses thereof
JP6721252B2 (ja) 皮膚Ｔ細胞リンパ腫（ＣＴＣＬ）を処置するためのｍｉＲ−１５５阻害剤
US20180237779A1 (en) Mir-92 inhibitors and uses thereof
US20180250325A1 (en) Mir-19 modulators and uses thereof
EP4590823A1 (fr) Composition de micro-arn anti-fibrotique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15840320

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2960387

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 250952

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2017513109

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12017500424

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2017/003018

Country of ref document: MX

REEP Request for entry into the european phase

Ref document number: 2015840320

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015840320

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20177008019

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2015315298

Country of ref document: AU

Date of ref document: 20150908

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017111775

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017004648

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112017004648

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170308